Drug intelligence / Profile preview

YPEG-rhGH

Development stage: Unknown
Lead developer: Xiamen Tebao Biological Engineering
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous

Overview

Yipesen (YPEG-rhGH) is a long-acting recombinant human growth hormone (rhGH) developed by Xiamen Tebao Bioengineering. It consists of rhGH (somatropin) conjugated to a 40 kDa Y-shaped polyethylene glycol (PEG) moiety using a proprietary PEGylation technology. This Y-shaped modification increases the molecule's hydrodynamic volume, thereby reducing renal clearance and extending its circulating half-life, which allows for once-weekly subcutaneous administration. Yipesen acts as an agonist at the growth hormone receptor (GHR), stimulating the JAK2/STAT5 signaling pathway and the subsequent production of insulin-like growth factor 1 (IGF-1). IGF-1 then mediates the growth-promoting and metabolic effects of the hormone. Yipesen was approved by the China National Medical Products Administration (NMPA) in June 2024 for the treatment of growth hormone deficiency in children and is currently in Phase 1 clinical development for adult growth hormone deficiency, including studies in elderly adults.

Brand names: Yipesen
Other names: Y-shaped PEGylated recombinant human growth hormone伊佩森

Targets

GHR (Growth hormone receptor)GHBP (Growth hormone binding protein)

Beyond the preview

Go deeper on YPEG-rhGH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YPEG-rhGH.

Explore the full profile